PROGLYCEM SUSPENSION Rx
Generic Name and Formulations:
Diazoxide 50mg/mL; chocolate-mint flavor; contains alcohol 7.25%.
Indications for PROGLYCEM SUSPENSION:
Management of hypoglycemia due to hyperinsulinism associated with: inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy in adults; leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis in infants and children.
Adults and Children:
Individualize. Infants and newborns: Initially 10mg/kg/day divided into 3 equal doses every 8hrs. Usual range: 8–15mg/kg divided into 2–3 equal doses every 8–12hrs. Adults and children: Initially 3mg/kg/day divided into 3 equal doses every 8hrs. Usual range: 3–8mg/kg divided into 2–3 equal doses every 8–12hrs. Refractory hypoglycemia: may require higher dosages. Discontinue if not effective after 2–3 weeks.
Functional hypoglycemia. Thiazide hypersensitivity.
Compromised cardiac reserve: may precipitate CHF. Hyperuricemia. History of gout. Renal impairment: consider reducing dose; evaluate serum electrolyte levels. Newborns with increased bilirubinemia. Monitor for respiratory distress (esp. in those with risk factors); discontinue if pulmonary hypertension is suspected. Monitor blood glucose, BUN, creatinine clearance, hematocrit, platelets, total and differential leukocyte counts, AST, serum uric acid periodically until stabilized. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Nondiuretic benzothiadiazine derivative.
Antihypertensives potentiated. Concomitant coumarin: may need to reduce dose of anticoagulant. Concomitant diphenylhydantoin may result in loss of seizure control. Concomitant thiazides, other diuretics may potentiate hyperglycemic and hyperuricemic effects. Inhibits glucagon-stimulated insulin release and causes false-negative insulin response to glucagon.
Sodium and fluid retention, diabetic ketoacidosis, hyperosmolar nonketotic coma, hirsuitism, hyperglycemia, glycosuria, GI upset, tachycardia, palpitations, increased serum uric acid, thrombocytopenia (may require discontinuation), neutropenia, rash, headache, weakness, malaise.
Susp—30mL (w. dropper)
Neurology Advisor Articles
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- Loss of Function Variants in LRRK1 and LRRK2 Not Linked to Parkinson Disease
- Smoking Promotes Disease Progression in Multiple Sclerosis
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- ZTlido Patch for Post-Shingles Pain Launching Soon
- Managing Complications of Intrathecal Baclofen Therapy
- Deep Brain Stimulation Reduces Tremor Symptoms in Parkinson Disease
- FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid
- Prevalence of Autoimmune Encephalitis in Herpes Simplex Encephalitis Explored